Markets
JPMorgan Downgrades Upstream Bio: Execution Risks Take Center Stage
JPMorgan has downgraded Upstream Bio, flagging execution risks that could weigh on the biotech's near-term trajectory. Here is a forensic breakdown of what the move signals and how traders should position around it.